Last reviewed · How we verify
TRIPTORELIN ACETATE, hCG
Triptorelin is a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased sex hormone production, combined with hCG for fertility preservation or ovarian stimulation.
Triptorelin is a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased sex hormone production, combined with hCG for fertility preservation or ovarian stimulation. Used for Fertility preservation or ovarian stimulation in assisted reproductive technology, Prostate cancer (standard triptorelin indication, though hCG combination is less common).
At a glance
| Generic name | TRIPTORELIN ACETATE, hCG |
|---|---|
| Sponsor | HaEmek Medical Center, Israel |
| Drug class | GnRH agonist |
| Target | GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Reproductive/Fertility |
| Phase | FDA-approved |
Mechanism of action
Triptorelin acetate acts as a gonadotropin-releasing hormone (GnRH) agonist, initially stimulating then desensitizing GnRH receptors on the pituitary gland to suppress LH and FSH secretion. When combined with hCG (human chorionic gonadotropin), this formulation may be used to support fertility outcomes or ovarian stimulation protocols, leveraging both the suppressive effects of triptorelin and the stimulatory effects of exogenous hCG.
Approved indications
- Fertility preservation or ovarian stimulation in assisted reproductive technology
- Prostate cancer (standard triptorelin indication, though hCG combination is less common)
Common side effects
- Hot flashes
- Headache
- Injection site reactions
- Mood changes
- Decreased libido
Key clinical trials
- Possible Action of Resveratrol in Improving the Outcomes of IVF/ICSI in Couples With Unexplained Infertility (NA)
- Effect of GnRH Agonist Treatment Protocols on Ovarian Reserve (NA)
- Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI (PHASE4)
- Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes. (PHASE4)
- Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI (PHASE4)
- Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients. (PHASE4)
- Comparison of Triggers in Double Ovarian Stimulation (DuoStim). (PHASE4)
- A Randomized Controlled Study of Different Trigger Modes of Antagonist Regimen in Patients With Low Ovarian Reserve (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TRIPTORELIN ACETATE, hCG CI brief — competitive landscape report
- TRIPTORELIN ACETATE, hCG updates RSS · CI watch RSS
- HaEmek Medical Center, Israel portfolio CI